Tazemetostat(TAZVERIK) is an innovative anti-disease drug that provides new therapeutic hope for patients with epithelioid sarcoma and relapsed or refractory follicular lymphoma.

How to use Tazemetostat?

Tazemetostat is a selective oral EZH2 (Enhancer of Zeste Homolog 2) inhibitor. EZH2 is an enzyme responsible for histone methylation in cells and has an important impact on cell proliferation and differentiation.

Recommended dosage and method of taking

The recommended dose of Tazemetostat is 800mg twice a day, and is administered orally, and can be taken with oral medication or not. Patients should swallow the tablets as a whole to avoid cutting, crushing or chewing to confirm the stable release of the drug.

Missing ingestion and dosage adjustment

If the patient misses one dose or vomits after taking the medicine, he does not need to take it again and continue to take the next dose as planned. Dosage adjustments to adverse reactions should be carried out under the guidance of a doctor to clarify the safety of treatment.

The dosage of Tazemetostat must be strictly followed by medical advice and the dosage is adjusted reasonably to achieve the best treatment effect.

Precautions for Tazemetostat medication

Before using Tazemetostat, patients should inform their doctor of their complete medical history and other medications being used (including prescription, over-the-counter and supplements) to avoid drug interactions.

Tissue risk for secondary malignant lesions

After treatment with Tazemetostat, there is a risk of secondary malignant tissue, so patients need to undergo long-term monitoring and seek medical attention in time once abnormalities are found.

Embryo-fetal toxicity

Tazemetostat is embryonic-fetal toxicity and should be avoided in pregnant women. Female patients with fertility should take effective contraception during the treatment period and within six months after discontinuation of the medication. Male patients also need to contraception within the corresponding time to protect the fetus from potential harm.

When using Tazemetostat, patients should fully understand its potential risks, especially secondary malignant lesions and embryo-fetal toxicity, follow medical advice, and clarify the safety of medication.

Tazemetostat's drug interaction

Tazemetostat may interact with other drugs, especially with strong or moderate CYP3A inhibitors and inducers.

Interaction with hormone contraceptive pills

Tazemetostat may cause some hormonal contraceptive pills to be ineffective, so female patients with fertility should use non-hormonal contraceptive methods during use of Tazemetostat to clarify the effect of contraceptives.

Drug interactions in special populations

Children, the elderly, and patients with renal and liver impairment should pay special attention to drug interactions when using Tazemetostat. Children should be cautious when taking medication. The elderly should adjust the medication according to the guidance of the doctor. Patients with liver and kidney function impairment may not need to adjust the dose, but the drug reaction should be closely monitored.

Tazemetostat interacts with a variety of drugs. Patients should inform the doctor in detail before use to avoid potential risks and make sure that the treatment goes smoothly.